World of DTC Marketing

JUNE 22, 2022

PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. Then there is the cost of generic drugs. bil­lion in 2020 if it had pur­chased 77 of 89 drugs from Cuban’s firm.

Pharmacy 227

Pharmacy Generic Drugs Life Science Branding 227

World of DTC Marketing

JULY 27, 2022

Pharma companies have very little control over patients’ prices for their Rxs. A drug’s out-of-pocket cost is primarily the result of decisions made by insurance companies and pharmacy benefit managers (PBMs). Insurers and PBMs have even devised schemes to overcharge patients for generic drugs.

Pharmacy 226

Pharmacy Generic Drugs Medicine Drugs 226

Pharmaceutical Technology

JUNE 5, 2023

Earlier this year, Sun Pharmaceutical Industries , one of India’s largest generic drug producers, reported a major cybersecurity breach , impacting its business operations. Pharma companies around the world have also faced similar threats , some of which have impacted national security and public health.

Genomics 276

Genomics Genome Compliance Regulation 276

pharmaphorum

AUGUST 20, 2020

Teva mainly administered the scheme through its specialty pharmacy, Advanced Care Scripts (ACS) with payments amounting to around $300 million during the period, according to the complaint. During that period Teva raised the price from around $17,000 per year to over $73,000 per year, the DoJ alleges.

Generic Drugs 115

Generic Drugs Sales Pharmacy Pharma Companies 115

pharmaphorum

SEPTEMBER 9, 2022

Pharma companies are “highly vulnerable” to the effects of climate change, due to their reliance on global networks. To meet the growing demand and market opportunity, a pharma company must ensure it has the resources, capacity, and supply chain to grow.”. Vulnerability . Making plans is not enough.

Production 105

Production Pharma Companies Generic Drugs Medicine 105

Pharmaceutical Technology

JULY 15, 2022

CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. In-house manufacturing the norm.

Insulin 328

Insulin Manufacturing Contract Manufacturing Production 328